Currently out of the existing stock ratings of Eric Schmidt, 32 are a BUY (100%).

Eric Schmidt

Work Performance Price Targets & Ratings Chart

Analyst Eric Schmidt, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 53.61% that have a potential upside of 23.62% achieved within 693 days.

Eric Schmidt’s has documented 62 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RNA, Avidity Biosciences  at 27-Jun-2025.

Wall Street Analyst Eric Schmidt

Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 1/2/2018. The price target of $338 was fulfilled within 1 day with a profit of $3.83 (1.15%) receiving and performance score of 11.46.

Average potential price target upside

BIIB Biogen CELG Celgene INCY yte AMGN Amgen ALXN Alexion Pharmaceuticals BLUE Bluebird bio AGIO Agios Pharm CRSP Crispr Therapeutics AG IMCR Immunocore Holdings Ltd IMTX Immatics NV RNA Avidity Biosciences  TNGX Tango Therapeutics ALMS Alumis Common Stock ADCT ADC Therapeutics SA AKCA Akcea Therapeutics CDTX Cidara Therapeutics PRTA Prothena plc RARE Ultragenyx SMMT Summit Therapeutics PLC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 22-Nov-2017

$225

$23.82 (11.84%)

$205

10 days ago
(30-Jan-2026)

24/43 (55.81%)

$45.11 (25.08%)

326

Hold Since 21-Oct-2021

$185

$-16.18 (-8.04%)

$180

13 days ago
(27-Jan-2026)

20/27 (74.07%)

$10.88 (6.25%)

204

Hold Since 08-Jan-2026

$190

$-11.18 (-5.56%)

$199

1 months 1 days ago
(08-Jan-2026)

2/5 (40%)

$4 (2.15%)

156

Hold Since 09-Dec-2024

$185

$-16.18 (-8.04%)

$180

1 months 2 days ago
(07-Jan-2026)

12/31 (38.71%)

$-1.91 (-1.02%)

188

Hold Since 31-Oct-2024

$156

$-45.18 (-22.46%)

$149

1 months 28 days ago
(12-Dec-2025)

24/49 (48.98%)

$-18.1 (-10.40%)

266

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Eric Schmidt?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?